Saltar al contenido
Merck

Antiviral Effects of Novel 2-Benzoxyl-Phenylpyridine Derivatives.

Molecules (Basel, Switzerland) (2020-03-25)
Yanhong Wei, Haijie Wang, Caili Xi, Ni Li, Dong Li, Chenguang Yao, Ge Sun, Hongmei Ge, Kanghong Hu, Qian Zhang
RESUMEN

Coxsackievirus B3 (CVB3) is the most common cause of acute and chronic viral myocarditis, primarily in children, while human adenovirus infections represent a significant cause of morbidity and mortality worldwide, in people of all ages. A series of novel 2-benzoxyl-phenylpyridine derivatives were evaluated for their potential antiviral activities against CVB3 and adenovirus type 7 (ADV7). Preliminary assays indicated that some of these compounds exhibited excellent antiviral effects on both CVB3 and ADV7 viruses; they could effectively inhibit virus-induced cytopathic effects, reduce viral progeny yields, and had similar or superior antiviral activities compared with the control drug, ribavirin. Further, these compounds targeted the early stages of CVB3 replication in cells, including viral RNA replication and protein synthesis, rather than inactivating the virus directly, inhibiting virus adsorption/entry, or affecting viral release from cells. Our data demonstrate that the tested 2-benzoxyl-phenylpyridine derivatives are effective inhibitors of CVB3 and ADV7, raising the possibility that these compounds might be feasible candidates for anti-viral agents.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Anticuerpo anti-virus de Coxsackie B3, clon 280-5F-4E-5E, clone 280-5F-4E-5E, Chemicon®, from mouse